Company presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
|
|
- Caroline Wilson
- 5 years ago
- Views:
Transcription
1 Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012
2 Forward-looking statements The presentation contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This presentation is not an offer of securities for sale in any country or jurisdiction, including the United States. Securities may not be sold to the public in the United States, in Australia, in Canada, in Japan, or in other relevant jurisdictions without complying with local registration requirements and other legal restrictions. Declaration by the official Corporate Financial Reporting Manager: The undersigned herewith attests, pursuant to Article 154-bis, paragraph 2 of the Italian Consolidated Law on Finance (Legislative Decree 58/1998), that the accounting disclosure contained in this presentation matches documentary evidence, corporate books, and accounting records. Enrico Cappelli, Chief Financial Officer, official Corporate Financial Reporting Manager MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
3 MolMed, an oncology focused company Listed on the Milan Stock Exchange (MLM) Net financial position: 33 M (Mar 31st 2012) 106 employees, 2/3 staff scientists Company core competencies: Recombinant proteins: Recombinant proteins NGR-hTNF: tumour vascular targeting agent expected first filing in 2013 Cell and gene therapy: Cell & gene therapy TK: cell therapy product expected filing in 2013 CMO activities for third parties: growing revenues MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
4 MolMed business model: innovation and risk mitigation Two innovative technologies with different business strategies Recombinant proteins Cell & gene therapy MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
5 MolMed business model: innovation and risk mitigation Two innovative technologies with different business strategies Recombinant proteins Cell & gene therapy NGR-hTNF Tumour vascular targeting Potential blockbuster Partnering for larger indications MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
6 MolMed business model: innovation and risk mitigation Two innovative technologies with different business strategies Recombinant proteins Cell & gene therapy NGR-hTNF Tumour vascular targeting Potential blockbuster TK Patient-specific product for high-risk leukemia Partnering for larger indications Own commercialisation (in EU & US) MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
7 MolMed business model: innovation and risk mitigation Two innovative technologies with different business strategies Recombinant proteins Cell & gene therapy NGR-hTNF TK CMO activities Tumour vascular targeting Potential blockbuster Patient-specific product for high-risk leukemia Patient-specific cell & gene therapies Partnering for larger indications Own commercialisation (in EU & US) R&D & production for third parties MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
8 ASCO 2012: overview of extensive clinical development efforts MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
9
10
11
12
13 NGR-hTNF: a selective vascular targeting agent Recombinant fusion trimeric protein: Structure of 1 monomer NGR binding to tumour blood vessels NGR peptide CD13 on tumour neovasculature htnf TNF-Receptor Endothelium marker (green) + NGR (red) Doses of 0.8 µg/sqm systematically show antitumour activity MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
14 Selective binding to angiogenic tumour vessels Human colon carcinoma Normal human colon Endothelium marker (green) + NGR (red) Endothelium marker (green) + NGR (red) NGR binds to tumour vessels of CRC and not to those of normal intestine MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
15 Product manufacturing on track for future global market requirements Cost-effectively obtained by fermentation in E.coli (one single gene construct) Development of commercial-scale manufacturing ongoing for liquid and lyophilised formulations MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
16 NGR-hTNF clinical development: 1 pivotal Ph III and 4 randomized Ph II trials ongoing Indication Trial code Phase I Phase II Phase III Solid tumours MTD EORTC Monotherapy Solid tumours low dose Solid tumours high dose Colorectal cancer Liver cancer Mesothelioma Mesothelioma/maintenance NGR002 NGR013 NGR006 NGR008 NGR010, NGR015 rand. NGR019 random. + doxorubicin Solid Tumours NGR003 Lung cancer/sclc Ovarian cancer Ovarian cancer Soft tissue sarcomas NGR007 NGR012 NGR018 random. NGR016 random. + Xelox Colorectal cancer NGR005 + cisplatin Solid tumours NGR004 ongoing completed Lung cancer /NSCLC NGR014 random. MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
17 SCLC: efficacy independent of tumour chemo-sensitivity Phase II Single arm + Doxorubicin (75mg/sqm) 2nd line Waterfall plot Platinum-resistant Platinum-sensitive Progressive disease Partial response Complete response Important responses independent of prior tumour chemo-sensitivity MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
18 Ovarian cancer: response-related long-term efficacy Phase II Single arm + Doxorubicin (60mg/sqm) 2nd line Spider plot Multiple strong and durable responses MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
19 Mesothelioma: effect of treatment intensification Phase II Single arm Monotherapy 2nd line OS by schedule in pts with disease control3 3-year follow-up data confirm the benefit of dose intensification and validate the design of the ongoing pivotal Phase III study MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
20 NSCLC: first data from a randomised study suggest efficacy in the squamous subset Phase II Randomized + Cisplatin and Gemcitabine 1st line Decrease in tumor size over treatment Overall survival (n=34) 30% of relative reduction in the risk of tumour progression and 50% relative reduction in the risk of death MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
21 Very low toxicity profile More than 500 patients treated so far: No grade 3-4 drug-related toxicity No cumulative toxicity No worsening of chemo-associated toxicities No pulmonary hemorrhage or bleeding events No dose delays, dose reductions or treatment discontinuations due to toxicity Suitable for long-term maintenance treatment MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
22 Potential predictor of efficacy investigated: treatment-induced chills Progression free survival by chills in mesothelioma About two thirds of patients experience chills during first infusions The onset of chills predicts greater treatment benefit MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
23 Data from five randomised studies expected over the next 18 months Non small-cell lung cancer (1st line) In combination with cisplatin-based chemotherapy Survival data expected in 2H 2012 Ovarian cancer (2nd line) In combination with doxorubicin Results expected in 1H 2013 Sarcomas (1st and 2nd line) In combination with doxorubicin or monotherapy Results expected in 2H 2013 MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
24 TK: a new technology for haematopoietic stem cell transplant Indication: haematopoietic stem cell transplants (HSCT) for high-risk leukaemias Unmet need: ~50% of patients candidate to HSCT miss a fully matched donor Without a transplant, high-risk leukemia patients have extremely low survival rate
25 TK therapy: provides a fully functional immune system Protection from infections Protection from leukaemia relapse No immunesuppression needed (prompt abrogation of GvHD by administration of ganciclovir) An option to high-risk leukemia patients in need of a transplant MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
26 Phase II data indicate that TK allows a transplant from a partially compatible donor Haplo-HSCT data (EBMT survey, 266 patients)1 Phase II TK: immune-reconstituted patients (22 patients)2 Median age 35 years 56 years Transplant-related mortality (at 50 months from HSCT) 50% 14% Leukaemia relapse 20-30% 10% 4-year disease-free survival 20-30% 45% GvHD - occurrence - control n.d. 50% 100%.reducing leukaemia relapse and transplant-related mortality resulting in longer disease-free survival MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
27 Ongoing pivotal Phase III trial (TK008) Enrolment planned: 170 patients, randomisation 3:1 in favour of TK Primary endpoint: disease-free survival Ongoing in Europe in 7 centers, further expansion in additional 10 in Europe and the US (following IND clearance in 2011) Planned application for Conditional Approval in early 2013 MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
28 CMO activities: on the market in growing cell and gene therapy field Core competencies since inception of the company in 1996 Manufacturing of TK for Phase III and commercialisation Growing interest from pharma companies in potentially revolutionary cell and gene therapies Agreement signed in 2011: up to 13.8 M over 4 years, 104% increase in revenues (1q 2012 vs 1q 2011) Opportunity for further industrial partnerships MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
29 TK: getting ready for the market Phase II long-term data available and pivotal Phase III trial under way Planned application for Conditional Approval in 2013 based on: Proof of efficacy Established long-term safety data High unmet medical need for patients lacking HLA-matched donor Orphan Drug designation + patent protection (with SPC) up to 2030 Small dedicated sales force required MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
30 NGR-hTNF: gearing up for regulatory approval Pivotal Phase III on track with enrolment, results expected by 2H 2013 Registration planned in mesothelioma as first indication: Low competition: no products in second-line treatment on the market or in Phase III development Orphan Drug designation + patent protection up to 2029 Potential predictor of efficacy identified MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
31 MolMed business model: innovation and risk mitigation Two innovative technologies with different business strategies Recombinant proteins Cell & gene therapy NGR-hTNF TK CMO activities Tumour vascular targeting Potential blockbuster Patient-specific product for high-risk leukemia Patient-specific cell & gene therapies Partnering for larger indications Own commercialisation (in EU & US) R&D & production for third parties MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
32 MolMed business model: innovation and risk mitigation Two innovative technologies with different business strategies Recombinant proteins Cell & gene therapy NGR-hTNF TK CMO activities Tumour vascular targeting Potential blockbuster Patient-specific product for high-risk leukemia Patient-specific cell & gene therapies Partnering for larger indications + Dedicated sales force for mesothelioma Own commercialisation (in EU & US) R&D & production for third parties Opportunities for partnerships MolMed S.p.A. Jefferies Global Healthcare Conference, 7 June
33 Thank you very much for your attention MolMed S.p.A. Via Olgettina Milan (Italy)
Company presentation. Jefferies Global Healthcare Conference New York, June 6, Claudio Bordignon Chairman and CEO
Company presentation Jefferies Global Healthcare Conference New York, June 6, 2013 Claudio Bordignon Chairman and CEO Forward-looking statements The presentation contains certain forward-looking statements.
More informationLeading the way in cell & gene therapy
Leading the way in cell & gene therapy Company presentation Inv $tival Biotech Showcase London (UK), November 18, 2016 From genes to therapy Forward-looking statements The presentation contains certain
More informationMolMed S.p.A. Company presentation
an integrated strategy to cure cancer MolMed S.p.A. Company presentation 2 nd Italian Stock Market Opportunities Conference Milan, September 17, 2009 Forward-looking statements This presentation may contain
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationJefferies Global Healthcare Conference New York 2014
Jefferies Global Healthcare Conference New York 2014 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationDendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationBuilding Shareholder Value
Building Shareholder Value June 4, 2014 Jefferies Healthcare Conference Tim Clackson, Ph.D. Hans Loland P r e s i d e n t o f R & D, C h i e f S c i e n t i f i c O f f i c e r with wife Cynthia A R I
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationtrabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal
trabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal 08 October 2010 The Scottish Medicines Consortium (SMC) has
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationNews Release. December 9, Not intended for UK-based media
Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72-9591 Investor Relations: +49 6151 72-3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationCompany presentation. September NASDAQ: ASLN TPEx: 6497
Company presentation September 2018 NASDAQ: ASLN TPEx: 6497 Disclaimer This presentation and the accompanying oral presentation contain forward-looking statements. These statements are based on the current
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationPath to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationYour Contacts. EMA ODD is an important regulatory milestone for avelumab in metastatic Merkel cell carcinoma (MCC)
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Lisa O Neill +44 1737 331536 Investor
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationTHE NEXT GROWTH PHASE
THE NEXT GROWTH PHASE Investor Briefing Non-Deal Roadshow March 2019 Melbourne Sydney CLINUVEL PHARMACEUTICALS LTD Darren Keamy, Chief Financial Officer Malcolm Bull, Investor Relations Manager ASX: CUV
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationJefferies 2015 Healthcare Conference
Jefferies 2015 Healthcare Conference Paul J. Hastings Chairman and Chief Executive Officer June 2, 2015 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements.
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More informationNews Release. Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab.
Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationFirst self-administered antibody therapy for HIV in late-stage clinical trials. CytoDyn Annual Meeting of Stockholders August 24, 2017
First self-administered antibody therapy for HIV in late-stage clinical trials CytoDyn Annual Meeting of Stockholders August 24, 2017 (OTCQB: CYDY) www.cytodyn.com Forward-Looking Statements This presentation
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationHALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationINODIFTAGENE Recombinant DNA Gene Therapy for Bladder Cancer
INODIFTAGENE Recombinant DNA Gene Therapy for Bladder Cancer 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of U.S. federal securities laws and Israeli
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationNOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation
Date 8 August 2017 Sydney, Australia ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Operations Office: Suite 3 Level 4 828 Pacific
More information